1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

GSK's Eyes Benlysta Expansion With First US FDA Lupus Nephritis Approval

 
• By Jessica Merrill

The new indication paves the way for Benlysta in a new patient population, as well as expansion in systemic lupus erythematosus, US specialty unit head Sheri Mullen said.

LONDON- JUNE, 2018: The GlaxoSmithKline headquarters building in Brentford, west London. A British global pharmaceuticals company.
GSK has a new indication for Benlysta • Source: Shutterstock

GlaxoSmithKline plc's Benlysta (belimumab) is the first drug approved by the US Food and Drug Administration for the treatment of adults with active lupus nephritis, the acute kidney disease caused by systemic lupus erythematosus (SLE). Benlysta has been approved in the US for SLE since 2011, but the new approval, for both the intravenous and subcutaneous versions, is a first for lupus nephritis.

GSK announced the approval on 17 December, with the company beating another close rival to the punch. Aurinia Pharmaceuticals...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from Therapy Areas

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 
• By Jessica Merrill

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.